GoodRx vs. Hims & Hers Health: Stagnation in Revenue Growth Compared

Hims & Hers Health is outpacing GoodRx with consistent sequential revenue growth, while GoodRx has shown flat quarter-over-quarter performance. Investors are advised to monitor the widening gap and its potential implications for future market positioning.

By Cory Renauer · Motley Fool · May 10, 2026, 12:24 UTC

GoodRx vs. Hims & Hers Health: Stagnation in Revenue Growth Compared

Tickers: $GDRX $HIMS

Topics: GoodRx Hims & Hers Health Pharmaceuticals Revenue Growth Telehealth

Read the full article at Motley Fool

More World news

Jim Cramer Advises Profit-Taking Following Jensen Huang's Resignation at Nvidia CNBC · November 12, 2026, 16:59 UTC
LexisNexis Report Shows Elevated U.S. Auto Insurance Shopping Volumes in Q3 2026 PR Newswire · November 12, 2026, 17:12 UTC
Suburban Propane Partners Outlines $60M-$70M Capital Expenditures for Fiscal 2027 Seeking Alpha · November 12, 2026, 17:00 UTC
Nvidia, Supermicro, and Megaspeed Face U.S. Department of Justice Probes Seeking Alpha · November 12, 2026, 17:00 UTC
Starbucks Implements Quarterly Performance-Based Bonuses for Baristas Seeking Alpha · November 12, 2026, 17:03 UTC
Jim Cramer Analyzes Nvidia Leadership Transition and Recommends AMD, Constellation Brands, and Kimberly-Clark CNBC · November 12, 2026, 16:55 UTC
Nvidia CEO Jensen Huang Resigns Amid Personal Scandal, Threatening $500 Billion AI Financing Plan CNBC · November 12, 2026, 16:55 UTC
Al Mouj Muscat Receives Three Architectural Awards at International and Arabian Property Awards 2026 PR Newswire · November 12, 2026, 17:01 UTC
SoftBank Reports $7.1 Billion Quarterly Loss Driven by Natural Gas Turbine Over-Ordering TechCrunch · November 12, 2026, 17:00 UTC
PayPal and Kiva Renew Long-Term Partnership to Support Global Microloans PR Newswire · November 12, 2026, 17:00 UTC